Osteal Therapeutics

San Clemente, United States Founded: 2013 • Age: 13 yrs
Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections
Request Access

About Osteal Therapeutics

Osteal Therapeutics is a company based in San Clemente (United States) founded in 2013.. Osteal Therapeutics has raised $126.4 million across 7 funding rounds from investors including Zimmer Biomet, Johnson & Johnson Innovation – JJDC and Gideon Strategic Partners. Osteal Therapeutics offers products and services including VT-X7. Osteal Therapeutics operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Horizon Therapeutics, among others.

  • Headquarter San Clemente, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Osteal Therapeutics, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $126.4 M (USD)

    in 7 rounds

  • Latest Funding Round
    $15.6 M (USD), Series D

    Oct 17, 2025

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Osteal Therapeutics

Osteal Therapeutics offers a comprehensive portfolio of products and services, including VT-X7. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Medication for treating orthopedic infections through clinical trials.

People of Osteal Therapeutics
Headcount 10-50
Employee Profiles 13
Employee Profiles
People
Logan Dahir
Director Of Product Management & Strategic Marketing
People
David Thompson
Chairman And Chief Executive Officer
People
Kathy Burke
Vice President, Market Access
People
Trey Putnam
Chief Operating Officer

Unlock access to complete

Funding Insights of Osteal Therapeutics

Osteal Therapeutics has successfully raised a total of $126.4M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $15.6 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 7
  • Last Round Series D — $15.6M
  • First Round

    (18 Apr 2018)

  • Investors Count 8
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2025 Amount Series D - Osteal Therapeutics Valuation

investors

May, 2024 Amount Series D - Osteal Therapeutics Valuation Zimmer Biomet
Sep, 2023 Amount Series C - Osteal Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Osteal Therapeutics

Osteal Therapeutics has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Zimmer Biomet, Johnson & Johnson Innovation – JJDC and Gideon Strategic Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital firm backed by Johnson & Johnson
Founded Year Domain Location
Healthcare venture capital investments are managed by HM Venture Partners.
Founded Year Domain Location
Medvest Capital is focused on investing in medical device companies.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Osteal Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Osteal Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Osteal Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Osteal Therapeutics

Osteal Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Horizon Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Pharmaceutical products are manufactured and marketed worldwide.
domain founded_year HQ Location
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
domain founded_year HQ Location
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
domain founded_year HQ Location
Traditional pharmaceutical medicines are developed for multiple health fields.
domain founded_year HQ Location
Developer of drugs for treating rare and autoimmune diseases
domain founded_year HQ Location
Developer of drugs for the treatment of multiple disorders
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Osteal Therapeutics

Frequently Asked Questions about Osteal Therapeutics

When was Osteal Therapeutics founded?

Osteal Therapeutics was founded in 2013 and raised its 1st funding round 5 years after it was founded.

Where is Osteal Therapeutics located?

Osteal Therapeutics is headquartered in San Clemente, United States. It is registered at San Clemente, California, United States.

Who is the current CEO of Osteal Therapeutics?

David Thompson is the current CEO of Osteal Therapeutics.

Is Osteal Therapeutics a funded company?

Osteal Therapeutics is a funded company, having raised a total of $126.4M across 7 funding rounds to date. The company's 1st funding round was a Series C of $23M, raised on Apr 18, 2018.

What does Osteal Therapeutics do?

Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections. The company lead product VT-X7 is for Periprosthetic joint infection and targets chronic bacterial PJI. Another drug candidate A-103 is for fungal PJI. The company offers its drug-device combination product for antibiotic therapy for local delivery to treat infected joint prostheses like bacterial and fungal infections for joints like shoulder, knee, and hip.

Who are the top competitors of Osteal Therapeutics?

Osteal Therapeutics's top competitors include Merck, Roivant Sciences and AbbVie.

What products or services does Osteal Therapeutics offer?

Osteal Therapeutics offers VT-X7.

Who are Osteal Therapeutics's investors?

Osteal Therapeutics has 8 investors. Key investors include Zimmer Biomet, Johnson & Johnson Innovation – JJDC, Gideon Strategic Partners, HM Venture Partners, and Prism Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available